CHRS
Coherus Oncology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 28 ▲ Three major passive institutional investors, Morgan Stanley, Wells F…
- Mar 9 ▲ Coherus Oncology reported strong revenue growth for LOQTORZI, with f…
- May 11 Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$…
- Jun 23 Contract: Coherus and Zumutor Biologics Announce Clinical Collaborat…
- Aug 17 Dividend: Coherus Oncology Announces Special Dividend of Biosimilar…
- Oct 14 FDA: Coherus Oncology to Host Webcast to Disclose Interim Tagmo…
- Oct 15 ▲ Short interest falls 46.6% to 12.45M
- Oct 29 ▲ Coherus Oncology announced interim clinical data from the TREGCHECK…
- Nov 9 ▼ Earnings: CHRS Q3 2026 Earnings: EPS $-0.25 (-11.7% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 8 added (0 new), 16 trimmed or exited.
- AnalystsBULLISH
10 of 12 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.225 → −$0.210 over 90 days. 1 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +2.1% to 12.71M shares. 8.2 days to cover, ≈8.2% of shares.
- TrendDOWNTREND
51% below its 50-day average. New closing low $0.5060 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $1.2M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.1M |
| CITIGROUP INC | DOUBLED | $186.5K |
| STRS OHIO | NEAR_EXIT | $82.5K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $45.7K |
| IEQ CAPITAL, LLC | NEAR_EXIT | $30.9K |
| Cerity Partners LLC | TRIM | $23.3K |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | $20.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +1382%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Guggenheim MAINTAIN | Buy |
| Aug 7, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Newton Charles W. Director Jun 5, 2026 | AWARD | 30,000 sh |
Newton Charles W. Director Jun 5, 2026 | AWARD | 60,000 sh |
Wahlstrom Mats Director Jun 5, 2026 | AWARD | 60,000 sh |
Wahlstrom Mats Director Jun 5, 2026 | AWARD | 30,000 sh |
O'Donnell-Tormey Jill Director Jun 5, 2026 | AWARD | 30,000 sh |
O'Donnell-Tormey Jill Director Jun 5, 2026 | AWARD | 60,000 sh |
Ryan Michael Lee Director Jun 5, 2026 | AWARD | 30,000 sh |
Ryan Michael Lee Director Jun 5, 2026 | AWARD | 60,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.21 | -$0.21–-$0.21 | +0.0% | $15.9M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 4 press releases · 2 bullish · 2 bearish · 1 mixed · 6 neutral- BEARISH INST-CLUSTERNov 16, 2026
In Q3 2026, 12 institutional investors reduced their CHRS positions (net -$863K) while only 4 added (net +$637K), a 3:1 seller ratio. The selling follows a November 9 earnings release that showed LOQTORZI revenue growth but also a strategic restructuring with 30% headcount reduction and a narrowed…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 9, 2026
Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per…
Monitor the upcoming FDA alignment on tagmokitug's expedited development path in second-line esophageal cancer and the trajectory of LOQTORZI revenue growth toward the $25M-$30M quarterly core cash…
- BULLISH 8-KOct 29, 2026
Coherus Oncology announced interim clinical data from the TREGCHECK program for tagmokitug, an…
The interim data provides clinical proof of concept for tagmokitug in ESCC, with response rates that compare favorably to standard-of-care benchmarks. Monitor for further data maturation and…
- NEUTRAL PRESS RELEASEOct 14, 2026
Coherus Oncology announced it will release interim clinical data for tagmokitug (anti-CCR8…
The October 28 data readout is the key near-term catalyst for CHRS. Investors should watch for efficacy and safety signals in the tagmokitug-toripalimab combination across multiple solid tumor…
All CHRS filing & press-release reports (15)
- INST-CLUSTER reportNov 16, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 14, 2026
- PRESS-RELEASE reportAug 17, 2026
- PRESS-RELEASE reportJul 22, 2026
- 8-K reportJun 15, 2026
- INST-CLUSTER reportJun 12, 2026
- DEFA14A reportMay 28, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportMay 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportMar 9, 2026
- PRESS-RELEASE reportMar 2, 2026
- INST-CLUSTER reportFeb 28, 2026